US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...
Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.
Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.
Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...
Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.
The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...